Results 1 to 10 of about 207,130 (329)

T cells specific to multiple Bet v 1 peptides are highly cross-reactive toward the corresponding peptides from the homologous group of tree pollens

Frontiers in Immunology, 2023
BackgroundAllergens from Fagales trees frequently cause spring allergy in Europe, North America, and some parts of Asia. The definition of the birch homologous group, which includes birch (Bet v), oak (Que a), alder (Aln g), hazel (Cor a), hornbeam (Car ...
Gitte Lund, Lars Harder Christensen, Jacob Ihlemann, Peter Sejer Andersen, Erik Wambre, Peter Adler Würtzen, Shashank Gupta   +6 more
doaj   +1 more source

A practical guide to prescribing sublingual immunotherapy tablets in North America for pediatric allergic rhinoconjunctivitis: an injection-free allergy immunotherapy option

Frontiers in Pediatrics, 2023
Allergic rhinoconjunctivitis (ARC) is a common disease that affects individuals of all ages. Pediatricians may be the first (and only) point of care for children with ARC.
Michael Blaiss, Lawrence DuBuske, Hendrik Nolte, Morten Opstrup, Karen Rance   +4 more
doaj   +1 more source

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Clinical and Translational Allergy, 2022
Background This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy‐tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective.
Mette Bøgelund, Ana Rosado Ingelmo, Jose María Ausín Ruiz, Adolfo Galán Vivó, Henrik Brandi, Mikkel Hasse Pedersen, Anne Sofie Ledgaard Loftager, Mark Aagren   +7 more
doaj   +1 more source

Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets

Current Therapeutic Research, 2022
: Background: Sublingual allergy immunotherapy tablets (SLIT-tablets) provide a well-tolerated and clinically efficacious treatment for allergic disease such as allergic rhinitis and allergic asthma. In SLIT, uptake of allergen by immune-competent cells
Takashi Yamamoto, PhD, Katsuyo Ohashi-Doi, PhD, Hiroki Matsuhara, BSc, Loes Verhoog, MSc, Morten Lindholm, PhD, Simon Lawton, MD, Kaare Lund, PhD   +6 more
doaj   +1 more source

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. [PDF]

, 2020
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Al-Holou, Wajd, Armas, Octavio, Kubota, Takafumi, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Raval, Kunil, Robinette, Natasha, Zhu, Viola W   +7 more
core   +1 more source

ITULAZAX® versus Alutard SQ® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective

Clinical and Translational Allergy, 2022
Background and aims Allergic rhinitis (AR) is an inflammatory disorder triggered by an allergic immune response to inhaled allergens. Birch pollen is the major allergenic tree pollen in parts of Europe.
Steen M. Rønborg, Tobias Sydendal Grand, Henrik Brandi, Richard F. Pollock   +3 more
doaj   +1 more source

Correction to: The impact of perennial allergic rhinitis with/without allergic asthma on sleep, work and activity level

Allergy, Asthma & Clinical Immunology, 2020
The first and corresponding author was unfortunately presented as Mercedes Rodriguez Romano. The correct author name is Mercedes Romano.
Mercedes Romano, Stephanie James, Emily Farrington, Richard Perry, Lisa Elliott   +4 more
doaj   +1 more source

Tudásmenedzsment és a felsőoktatási intézmény, mint vállalat = Knowledge Management and the University as a Company [PDF]

, 2011
Purpose: ALK rearrangement detection using FISH is the standard test to identify patients with non–small cell lung carcinoma (NSCLC) eligible for treatment with ALK inhibitors. Recently, ALK protein expression in resectable NSCLC showed predictive value.
De Langen, A. J., Dingemans, A. M.C., Groen, H. J.M., Hendriks, L., Hiltermann, T. J.N., Looijen-Salamon, M., Mastik, M. F., Pelgrim, R., Riemersma, S., Schuuring, E., Speel, E. J.M., Staal-Van Den Brekel, J., T Hart, N., Timens, W., Van Den Berg, A., Van Den Borne, B. E., Van Der Heijden, E. H.F.M., Van Der Wekken, A. J., Werner, N.   +18 more
core   +6 more sources

Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.

The Lancet Regional Health. Europe, 2022
Summary: Background: Allergen immunotherapy (AIT) is the only causal treatment for respiratory allergy. Long-term real-life effectiveness of AIT remains to be demonstrated beyond the evidence from randomised controlled trials (RCTs).
Benedikt Fritzsching, Marco Contoli, Celeste Porsbjerg, Sarah Buchs, Julie Rask Larsen, Lisa Elliott, Mercedes Romano Rodriguez, Nick Freemantle   +7 more
doaj   +1 more source

The SQ HDM SLIT‐Tablet is safe and well tolerated in patients with House Dust Mite allergic rhinitis with or without asthma: A “real‐life” French study

Clinical and Translational Allergy, 2022
Background The SQ House Dust Mite (HDM) SubLingual ImmunoTherapy (SLIT)‐Tablet (Acarizax) is the only allergen immunotherapy authorized by European regulatory authorities to treat HDM‐induced allergic asthma (AA) that is not well‐controlled by inhaled ...
Pascal Demoly, Christophe Leroyer, Elie Serrano, Annelore Le Maux, Gabrielle Magnier, Antoine Chartier   +5 more
doaj   +1 more source